203 related articles for article (PubMed ID: 20378407)
1. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Ree AH; Dueland S; Folkvord S; Hole KH; Seierstad T; Johansen M; Abrahamsen TW; Flatmark K
Lancet Oncol; 2010 May; 11(5):459-64. PubMed ID: 20378407
[TBL] [Abstract][Full Text] [Related]
2. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.
Kalanxhi E; Risberg K; Barua IS; Dueland S; Waagene S; Andersen SN; Pettersen SJ; Lindvall JM; Redalen KR; Flatmark K; Ree AH
Cancer Res Treat; 2017 Apr; 49(2):374-386. PubMed ID: 27488871
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Doi T; Hamaguchi T; Shirao K; Chin K; Hatake K; Noguchi K; Otsuki T; Mehta A; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):87-95. PubMed ID: 22234637
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
Wilson PM; El-Khoueiry A; Iqbal S; Fazzone W; LaBonte MJ; Groshen S; Yang D; Danenberg KD; Cole S; Kornacki M; Ladner RD; Lenz HJ
Cancer Chemother Pharmacol; 2010 Apr; 65(5):979-88. PubMed ID: 20062993
[TBL] [Abstract][Full Text] [Related]
5. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
Bratland A; Dueland S; Hollywood D; Flatmark K; Ree AH
Radiat Oncol; 2011 Apr; 6():33. PubMed ID: 21473790
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Choi CYH; Wakelee HA; Neal JW; Pinder-Schenck MC; Yu HM; Chang SD; Adler JR; Modlin LA; Harsh GR; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):16-21. PubMed ID: 28816142
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
Ree AH; Saelen MG; Kalanxhi E; Østensen IH; Schee K; Røe K; Abrahamsen TW; Dueland S; Flatmark K
PLoS One; 2014; 9(2):e89750. PubMed ID: 24587009
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
Fujiwara Y; Yamamoto N; Yamada Y; Yamada K; Otsuki T; Kanazu S; Iwasa T; Hardwick JS; Tamura T
Cancer Sci; 2009 Sep; 100(9):1728-34. PubMed ID: 19575752
[TBL] [Abstract][Full Text] [Related]
11. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM
Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Kang YK
Br J Cancer; 2016 May; 114(11):1185-90. PubMed ID: 27172248
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
[TBL] [Abstract][Full Text] [Related]
14. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Munster PN; Marchion D; Thomas S; Egorin M; Minton S; Springett G; Lee JH; Simon G; Chiappori A; Sullivan D; Daud A
Br J Cancer; 2009 Oct; 101(7):1044-50. PubMed ID: 19738609
[TBL] [Abstract][Full Text] [Related]
17. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
Rubin EH; Agrawal NG; Friedman EJ; Scott P; Mazina KE; Sun L; Du L; Ricker JL; Frankel SR; Gottesdiener KM; Wagner JA; Iwamoto M
Clin Cancer Res; 2006 Dec; 12(23):7039-45. PubMed ID: 17145826
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Maeng J; Kim SY; Koo DH; Park I; Kang YK
Invest New Drugs; 2014 Apr; 32(2):271-8. PubMed ID: 23712440
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
